Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says

BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says

MT newswireMT newswire2026/10/12 17:02
01:02 PM EDT, 10/12/2026 (MT Newswires) -- BioAge Labs' (BIOA) shift toward diabetic macular edema and away from cardiovascular disease leaves an uncertain path for its lead drug candidate, BGE-102, UBS Securities said Sunday in a report. UBS said stepping back from atherosclerotic cardiovascular disease reduces BioAge's exposure to what could be a large market and may put the program behind competitors on development timelines. BioAge may revisit the heart-disease indication if future data from other companies strengthen the case, though that isn't its base expectation, the report said. UBS described BGE-102 as an experimental pill aimed at calming an overactive immune response. The drug may be differentiated because it reaches the central nervous system, lowers interleukin-1, a key inflammation signal, and binds to a distinct site on the NLRP3 protein. The phase 2 diabetic macular edema readout expected in H2 2027 is the company's main catalyst, the report said. UBs initiated coverage of BioAge stock with a neutral rating with $8 price target. Price: 6.00, Change: -0.34, Percent Change: -5.36
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16